Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Molecular medicine today

• Publication date

  1997-02-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S1357-4310(96)10058-7PMID 9060004
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Development of a single-shot subunit vaccine for HIV-1.

  1997cited by this paper
• Adjuvant activity of iscoms; effect of ratio and co-incorporation of antigen and adjuvant.

  1996cited by this paper
• Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines.

  1996cited by this paper
• A month–long effect from a single injection of microencapsulated human growth hormone

  1996cited by this paper
• Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection

  1996cited by this paper
• Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

  1996cited by this paper
• Monophosphoryl Lipid A as an Adjuvant

  1995cited by this paper
• A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy

  1995cited by this paper
• Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres

  1995cited by this paper
• Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes.

  1995cited by this paper
• Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells.

  1995cited by this paper
• Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles.

  1995cited by this paper
• The preparation, characterization and pre-clinical evaluation of an orally administered HIV-I vaccine, consisting of a branched peptide immunogen entrapped in controlled release microparticles

  1995cited by this paper
• A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected].

  1995cited by this paper
• Adjuvant properties of aluminum and calcium compounds.

  1995cited by this paper
• Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.

  1995cited by this paper
• Enhancement of humoral response against human influenza vaccine with the simple submicron oil/water emulsion adjuvant MF59.

  1995cited by this paper
• Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres

  1995cited by this paper
• Vaccine Design

  1995cited by this paper
• Antibody and cytotoxic T-cell responses to soluble hepatitis B virus (HBV) S antigen in mice: implication for the pathogenesis of HBV-induced hepatitis

  1994cited by this paper
• Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.

  1994cited by this paper
• Probing the structure‐activity relationship of Escherichia coli LT‐A by site‐directed mutagenesis

  1994cited by this paper
• Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers.

  1994cited by this paper
• Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles.

  1994cited by this paper
• Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma.

  1994cited by this paper
• Novel Delivery Systems for Oral Vaccines

  1994cited by this paper
• Handbook of mucosal immunology

  1994cited by this paper
• 2 – Structure and Function of Intestinal Mucosal Epithelium

  1994cited by this paper
• Advances in Influenza Virus Vaccine Research a

  1993cited by this paper
• Adjuvants--a balance between toxicity and adjuvanticity.

  1993cited by this paper
• Protection against vaginal SIV transmission with microencapsulated vaccine.

  1993cited by this paper
• Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles.

  1993cited by this paper
• Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres

  1992cited by this paper
• The age-dependent risk of postvaccination complications in vaccinees with smallpox vaccine.

  1992cited by this paper
• Immunologic aspects of liposomes: presentation and processing of liposomal protein and phospholipid antigens.

  1992cited by this paper
• Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen.

  1992cited by this paper
• Controlled release microparticles for vaccine development.

  1991cited by this paper
• Biodegradable microparticles as controlled release antigen delivery systems.

  1991cited by this paper
• Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies

  1991cited by this paper
• Phagocytosis of polymer microspheres by macrophages

  1990cited by this paper
• Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the peyer's patches

  1990cited by this paper
• Immunological adjuvants: a role for liposomes.

  1990cited by this paper
• Prolonged delivery of peptides by microcapsules

  1987cited by this paper
• An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity.

  1986cited by this paper

• Nano/Micro-Enabled Modification and Innovation of Conventional Adjuvants for Next-Generation Vaccines

  2025cites this paper
• Influence of adjuvant type and route of administration on the immunogenicity of Leishmania-derived tick-borne encephalitis virus-like particles - a recombinant vaccine candidate.

  2024cites this paper
• Evaluation of Biodegradable Microparticles for Mucosal Vaccination Against Diphtheria Toxoid: Nasal Efficacy Studies in Guinea Pigs.

  2022cites this paper
• ASIA syndrome and endocrine autoimmune disorders.

  2020cites this paper
• Efficacy of Montanide (IMS 3015) as an adjuvant for an inactivated Rift Valley fever (RVF) vaccine in sheep.

  2019cites this paper
• Excipient Development For Pharmaceutical, Biotechnology, And Drug Delivery Systems

  2019cites this paper
• Techniques Employed in Production of Traditional Vaccines Commonly Used by Military Forces: A Review

  2019cites this paper
• Infection Prevention: Oil- and Lipid-Containing Products in Vaccinology

  2018cites this paper
• AS03-Adjuvanted H5N1 Avian Influenza Vaccine Modulates Early Innate Immune Signatures in Human Peripheral Blood Mononuclear Cells

  2018cites this paper
• Plant Sources, Extraction Methods, and Uses of Squalene

  2018cites this paper
• Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled Trial

  2017cites this paper
• Comparative Parametric and Emission Characteristics of Single Cylinder Spark Ignition Engine Using Gasoline, Ethanol, and H₂O as Micro Emulsion Fuels

  2017cites this paper
• Nanoparticulate carrier(s): an emerging paradigm in new generation vaccine development

  2017cites this paper
• New Horizons in the Development of Novel Needle-Free Immunization Strategies to Increase Vaccination Efficacy.

  2016cites this paper
• Vaccines and vaccination for avian influenza in poultry.

  2016cites this paper
• Recent Advances of Vaccine Adjuvants for Infectious Diseases

  2015cites this paper
• Co-administration of non-carrier nanoparticles boosts antigen immune response without requiring protein conjugation.

  2014cites this paper
• Immunogenecity D Efficacy of Locally Prepared Montanide-oil Based H5N2 AI Vaccine Containing Flagellin As Immune Enhancer

  2014cites this paper
• Ultra Stable Glassy State Vaccines Containing Adjuvants

  2014cites this paper
• Nanoparticle vaccines.

  2014cites this paper
• Liposomes as nanovaccine delivery systems.

  2014cites this paper
• This information is current as Differentiation toward Dendritic Cells Chemoattractants and Enhance Monocyte MF59 Induce Monocyte and Granulocyte The Adjuvants Aluminum Hydroxide and

  2013cites this paper
• Immunobioengineering Approaches Towards Combinatorial Delivery of Immune-Modulators and Antigens

  2013cites this paper
• Formulation Approaches and Strategies for Vaccines and Adjuvants

  2013cites this paper
• Biodegradable microparticles covalently linked to surface antigens of the scuticociliate parasite P. dicentrarchi promote innate immune responses in vitro.

  2013cites this paper
• Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine.

  2012cites this paper
• Multi-Compartmental Delivery Systems for Peptide and DNA Vaccines in Melanoma Immunotherapy

  2012cites this paper
• Strain dependent protection conferred by Lactobacillus spp. administered orally with a Salmonella Typhimurium vaccine in a murine challenge model.

  2012cites this paper
• Microemulsions - A Brief Introduction

  2012cites this paper
• Immune responses to the oral administration of recombinant Bacillus subtilis expressing multi-epitopes of foot-and-mouth disease virus and a cholera toxin B subunit.

  2011cites this paper
• Liposomal vaccine delivery systems

  2011cites this paper
• Miscellaneous Forms of Drug Delivery

  2011cites this paper
• Transcutaneous delivery of a nanoencapsulated antigen: induction of immune responses.

  2010cites this paper
• Protection against pneumonic plague following oral immunization with a non-replicating vaccine.

  2010cites this paper
• Innovative vaccine production technologies: The evolution and value of vaccine production technologies

  2009cites this paper
• The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells

  2009cites this paper
• Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control

  2009cites this paper
• Immune modulators with defined molecular targets: cornerstone to optimize rational vaccine design.

  2009cites this paper
• Immune modulators with defined molecular targets: Cornerstone to optimize rational vaccine design

  2008cites this paper
• Enhanced mucosal and systemic immune response with squalane oil-containing multiple emulsions upon intranasal and oral administration in mice

  2008cites this paper
• Aplicabilidade do antígeno tetânico conjugado com derivados do Monometoxi-polietilenoglicol.

  2008cites this paper
• The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1

  2008cites this paper
• A chimeric alphavirus RNA replicon gene-based vaccine for human parainfluenza virus type 3 induces protective immunity against intranasal virus challenge.

  2007cites this paper
• The science of adjuvants

  2007cites this paper
• Immunodominant Francisella tularensis antigens identified using proteome microarray. ©Crown Copyright 2007 Dstl

  2007cites this paper
• Materials in particulate form for tissue engineering. 1. Basic concepts

  2007cites this paper
• Immunological responses after immunisation of mice with microparticles containing antigen and single stranded RNA (polyuridylic acid).

  2006cites this paper
• Excipients Used in Vaccines

  2006cites this paper
• Pathogen recognition and development of particulate vaccines: does size matter?

  2006cites this paper
• Vaccination of mice against intestinal Trichinella spiralis infections by oral administration of antigens microencapsulated in methacrilic acid copolymers.

  2006cites this paper
• 18 Used in Vaccines

  2006cites this paper
• Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses.

  2006cites this paper
• Immune responses in mice of beta-galactosidase adsorbed or encapsulated in poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres.

  2005cites this paper
• Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy

  2005cites this paper
• A Novel Mucosal Vaccine Against Foot-and-Mouth Disease Virus Induces Protection in Mice and Swine

  2005cites this paper
• A HER-2/neu peptide admixed with PLA microspheres induces a Th1-biased immune response in mice.

  2005cites this paper
• Distinctive patterns of autoimmune response induced by different types of mineral oil.

  2004influential citation
• Polymerised liposomes as intranasal vaccine adjuvants.

  2004cites this paper
• Improved Antigen Delivery Systems with PLGA Microsphere for a Single-Step Immunization

  2004cites this paper
• Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

  2004cites this paper
• Mucosal adjuvants and delivery systems for protein‐, DNA‐ and RNA‐based vaccines

  2004cites this paper
• New recombinant vaccines based on the use of prokaryotic antigen-display systems

  2004cites this paper
• PLA and PLGA microspheres of beta-galactosidase: Effect of formulation factors on protein antigenicity and immunogenicity.

  2004cites this paper
• High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha.

  2004cites this paper
• Aplicación intranasal de vacunas. Estado actual y perspectivas

  2003cites this paper
• Microparticles as vaccine adjuvants and delivery systems

  2003cites this paper
• Antitumor Efficacy Correlation between CD 8 T Cell Response Tumor-Specific Antigen Reveals a against a Weakly Immunogenic Self Individual Analysis of Mice Vaccinated

  2003cites this paper
• Tailored delivery of active keratinocyte growth factor from biodegradable polymer formulations.

  2003cites this paper
• Individual Analysis of Mice Vaccinated against a Weakly Immunogenic Self Tumor-Specific Antigen Reveals a Correlation between CD8 T Cell Response and Antitumor Efficacy 1

  2003cites this paper
• Advances in vaccine adjuvants for infectious diseases.

  2003cites this paper
• Immunotherapy of melanoma: principles

  2003cites this paper
• Recent Advances in Vaccine Adjuvants

  2002cites this paper
• Tools to Rapidly Produce and Screen Biodegradable Polymer and Sol-Gel-Derived Xerogel Formulations

  2002cites this paper
• Improved immune response from biodegradable polymer particles entrapping tetanus toxoid by use of different immunization protocol and adjuvants.

  2002cites this paper
• Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid.

  2001cites this paper
• Recent developments in adjuvants for vaccines against infectious diseases.

  2001cites this paper
• Enhanced immune response with a combination of alum and biodegradable nanoparticles containing tetanus toxoid

  2001cites this paper
• Defined Synthetic Vaccines

  2001cites this paper
• The Adjuvant MF59: A 10-Year Perspective Gary Ott, Ramachandran Radhakrishnan,

  2000cites this paper
• Advances in vaccine adjuvants

  1999cites this paper
• Immunogenicity of Outer Membrane Proteins in a Lipopolysaccharide-Deficient Mutant of Neisseria meningitidis: Influence of Adjuvants on the Immune Response

  1999cites this paper
• Analysis of the ability of five adjuvants to enhance immune responses to a chimeric plant virus displaying an HIV-1 peptide.

  1999cites this paper
• Analysis of local and systemic immunological responses after intra-tracheal, intra-nasal and intra-muscular administration of microsphere co-encapsulated Yersinia pestis sub-unit vaccines.

  1998cites this paper
• A comparison of biodegradable microparticles and MF59 as systemic adjuvants for recombinant gD from HSV-2.

  1998cites this paper
• Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization.

  1998cites this paper
• Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A.

  1998cites this paper
• Recent advances in immunological adjuvants: the development of particulate antigen delivery systems.

  1998cites this paper
• Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines.

  1998cites this paper